MARKET

SLN

SLN

Silence Therapeutics Plc
NASDAQ
6.98
+0.19
+2.80%
After Hours: 6.83 -0.15 -2.15% 18:04 05/13 EDT
OPEN
6.73
PREV CLOSE
6.79
HIGH
7.07
LOW
6.70
VOLUME
56.52K
TURNOVER
--
52 WEEK HIGH
8.40
52 WEEK LOW
3.689
MARKET CAP
329.70M
P/E (TTM)
-3.7205
1D
5D
1M
3M
1Y
5Y
1D
Silence Therapeutics to Participate in H.C. Wainwright BioConnect Investor Conference
Barchart · 1d ago
Weekly Report: what happened at SLN last week (0504-0508)?
Weekly Report · 2d ago
Analysts’ Top Healthcare Picks: Silence Therapeutics (SLN), Aclaris Therapeutics (ACRS)
TipRanks · 5d ago
Silence Therapeutics price target lowered to $27 from $35 at Chardan
TipRanks · 5d ago
Analysts Are Bullish on These Healthcare Stocks: Tectonic Therapeutic (TECX), Celldex (CLDX)
TipRanks · 6d ago
Analysts Are Bullish on These Healthcare Stocks: Silence Therapeutics (SLN), Zura Bio (ZURA)
TipRanks · 6d ago
Silence Therapeutics reports Q1 EPS (11c) vs. (20c) last year
TipRanks · 6d ago
Silence Therapeutics GAAP EPS of -$0.11, revenue of $0.4M
Seeking Alpha · 6d ago
More
About SLN
Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The Company leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The Company focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca.

Webull offers Silence Therapeutics PLC - ADR stock information, including NASDAQ: SLN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLN stock methods without spending real money on the virtual paper trading platform.